BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23142226)

  • 21. Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1).
    Oosterheert W; Gros P
    J Biol Chem; 2020 Jul; 295(28):9502-9512. PubMed ID: 32409586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoprotein A34, a novel target for antibody-based cancer immunotherapy.
    Scanlan MJ; Ritter G; Yin BW; Williams C; Cohen LS; Coplan KA; Fortunato SR; Frosina D; Lee SY; Murray AE; Chua R; Filonenko VV; Sato E; Old LJ; Jungbluth AA
    Cancer Immun; 2006 Jan; 6():2. PubMed ID: 16405301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
    Lin TY; Park JA; Long A; Guo HF; Cheung NV
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders.
    Liang Y; Xing X; Beamer MA; Swindell WR; Sarkar MK; Roberts LW; Voorhees JJ; Kahlenberg JM; Harms PW; Johnston A; Gudjonsson JE
    J Allergy Clin Immunol; 2017 Apr; 139(4):1217-1227. PubMed ID: 27884600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-Transmembrane Epithelial Antigen of Prostate 1 (STEAP1) Has a Single b Heme and Is Capable of Reducing Metal Ion Complexes and Oxygen.
    Kim K; Mitra S; Wu G; Berka V; Song J; Yu Y; Poget S; Wang DN; Tsai AL; Zhou M
    Biochemistry; 2016 Dec; 55(48):6673-6684. PubMed ID: 27792302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer.
    Wu HT; Chen WJ; Xu Y; Shen JX; Chen WT; Liu J
    Biomed Res Int; 2020; 2020():9578484. PubMed ID: 32802887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer.
    Liu T; Niu X; Li Y; Xu Z; Chen J; Xu G
    World J Surg Oncol; 2022 Mar; 20(1):96. PubMed ID: 35346237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a New Transcriptional Co-Regulator of STEAP1 in Ewing's Sarcoma.
    Markey FB; Romero B; Parashar V; Batish M
    Cells; 2021 May; 10(6):. PubMed ID: 34073779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis.
    Yokoe T; Tanaka F; Mimori K; Inoue H; Ohmachi T; Kusunoki M; Mori M
    Cancer Res; 2008 Feb; 68(4):1074-82. PubMed ID: 18281482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MHC Class I-Restricted TCR-Transgenic CD4
    Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
    Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
    Altvater B; Kailayangiri S; Theimann N; Ahlmann M; Farwick N; Chen C; Pscherer S; Neumann I; Mrachatz G; Hansmeier A; Hardes J; Gosheger G; Juergens H; Rossig C
    Cancer Immunol Immunother; 2014 Oct; 63(10):1047-60. PubMed ID: 24973179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody.
    Esmaeili SA; Nejatollahi F; Sahebkar A
    Anticancer Agents Med Chem; 2018; 18(12):1674-1679. PubMed ID: 29219059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
    Xu M; Evans L; Bizzaro CL; Quaglia F; Verrillo CE; Li L; Stieglmaier J; Schiewer MJ; Languino LR; Kelly WK
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
    Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
    Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of glycerol feeding profiles on STEAP1 biosynthesis by Komagataella pastoris using a methanol-inducible promoter.
    Duarte DR; Barroca-Ferreira J; Gonçalves AM; Santos FM; Rocha SM; Pedro AQ; Maia CJ; Passarinha LA
    Appl Microbiol Biotechnol; 2021 Jun; 105(11):4635-4648. PubMed ID: 34059939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target molecules in specific immunotherapy against prostate cancer.
    Harada M; Noguchi M; Itoh K
    Int J Clin Oncol; 2003 Aug; 8(4):193-9. PubMed ID: 12955573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
    Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
    Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.